The current price of NVAX is $9.78 — it has decreased by 8.17% since the previous close. Data as of Nov 5, 2026.
NVAX is down 4.77% over the past week, down 22.13% over the past month and up 27.18% over the past year. The price is above its 200-day moving average of $9.32.
Of the 9 analysts covering Novavax, Inc., 5 rate it a buy, 1 rates it a hold, 1 rates it a sell and 2 rate it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Novavax, Inc. has a market capitalization of $1.61B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Novavax, Inc. posted a loss of $0.19 per share against an estimate of -$0.346, beating expectations by 45.08%. Upcoming reports are listed in the earnings calendar.
Novavax, Inc. reported revenue of $68.3M in its most recent quarter, which has decreased by 3.05% compared with the same quarter a year earlier. Analysts had expected $50.42M.
Novavax, Inc. has not paid any dividends over the past year.
Companies most comparable to Novavax, Inc. include Moderna, Inc., BioNTech SE, Vaxcyte, Inc., Valneva SE and Emergent BioSolutions Inc.
In the latest trading session NVAX moved between $9.39 and $10.68, a range of 13.19% of its current price.
Over the past 52 weeks NVAX has traded between $6.20 and $13.39. The current price is 26.96% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.